Retrospective Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2016; 22(41): 9186-9195
Published online Nov 7, 2016. doi: 10.3748/wjg.v22.i41.9186
Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus
Krzysztof Domagalski, Małgorzata Pawłowska, Agnieszka Zaleśna, Małgorzata Pilarczyk, Paweł Rajewski, Waldemar Halota, Andrzej Tretyn
Krzysztof Domagalski, Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, 87-100 Toruń, Poland
Małgorzata Pawłowska, Małgorzata Pilarczyk, Waldemar Halota, Department of Paediatric Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-030 Bydgoszcz, Poland
Agnieszka Zaleśna, Paweł Rajewski, Provincial Infectious Diseases Hospital in Bydgoszcz, 85-030 Bydgoszcz, Poland
Andrzej Tretyn, Department of Plant Physiology and Biotechnology, Nicolaus Copernicus University, 87-100 Toruń, Poland
Author contributions: Domagalski K and Pawłowska M designed the research; Domagalski K and Zaleśna A performed the research; Zaleśna A, Pilarczyk M and Rajewski P collected the data; Pawłowska M, Halota W and Tretyn A reviewed this article; Domagalski K analysed the data and wrote the paper; and all authors have read and approved the final version to be published.
Institutional review board statement: The study was reviewed and approved by the NCU Bioethics Committee at Collegium Medicum NCU.
Informed consent statement: The patients’ legal guardians and all patients older than 16 signed a written informed consent.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Małgorzata Pawłowska, MD, PhD, Department of Paediatric Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, Floriana 12, 85-030 Bydgoszcz, Poland. mpawlowska@cm.umk.pl
Telephone: +48-523-255605 Fax: +48-523-255650
Received: June 27, 2016
Peer-review started: June 27, 2016
First decision: August 8, 2016
Revised: August 31, 2016
Accepted: September 28, 2016
Article in press: September 28, 2016
Published online: November 7, 2016
Processing time: 132 Days and 13.1 Hours
Core Tip

Core tip: The limited efficacy and side effects associated with IFN treatment limit its clinical use in paediatric patients with chronic hepatitis B (CHB). Therefore, pretreatment predictors are required to identify those patients at highest risk for treatment response failure. OAS and IL28B are well-known IFN-induced antiviral pathway players; however, the impact of host-related genetic variability in the IL28B and OAS genes on response rates to IFN therapy in CHB paediatric patients has not been studied. The results of our study show an association between IL28B rs12979860, OASL rs10849829 and OAS haplotypes and final IFN-treatment response in Caucasian CHB children.